New drug combo aims to protect kidneys in heart patients

NCT ID NCT07304817

Recruiting now Disease control Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two different drugs, vicadrostat and spironolactone, both taken with empagliflozin, to see how they affect kidney function and protein levels in blood and urine. The trial involves 100 adults with chronic kidney disease and heart disease or heart failure. Participants will take one of the two drug combinations daily for 26 weeks to understand which approach works better for kidney protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic kidney disease heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASES CKD HEART FAILURE

Contacts and locations

Locations

Delphinium
RECRUITING

Groningen, Provincie Groningen, 9713GZ, Netherlands
University Medical Center Groningen
RECRUITING

Groningen, Provincie Groningen, 9713GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.